炔雌醇环丙孕酮联合吡格列酮治疗多囊卵巢综合征患者的临床效果

Clinical efficacy of ethinylestradiol and cyproterone acetate combined with pioglitazone in the treatment of patients with polycystic ovary syndrome

目的探讨炔雌醇环丙孕酮联合吡格列酮治疗多囊卵巢综合征(PCOS)患者的临床效果。方法选取我院收治的165例PCOS患者为研究对象,按照治疗方案的不同将其分为参照组(n=82)和研究组(n=83)。参照组采用炔雌醇环丙孕酮治疗,研究组采用炔雌醇环丙孕酮联合吡格列酮治疗。比较两组的治疗效果。结果治疗后,研究组的T、FSH、FPG、FIns、HOMA-IR、CRP、TNF-α水平均低于参照组(P<0.05);两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论采用炔雌醇环丙孕酮联合吡格列酮治疗PCOS,能改善胰岛素抵抗,降低血清炎性因子及生殖激素水平,且安全性高。

Objective To investigate the clinical efficacy of ethinylestradiol and cyproterone acetate combined with pioglitazone in patients with polycystic ovary syndrome(PCOS).Methods A total of 165 patients with PCOS admitted in our hospital were selected as the research objects,and divided into reference group(n=82)and study group(n=83)according to different treatment schemes.The reference group was treated with ethinylestradiol and cyproterone acetate,and the study group was treated with ethinylestradiol and cyproterone acetate combined with pioglitazone.The therapeutic effects of the two groups were compared.Results After treatment,the levels of T,FSH,FPG,FIns,HOMA-IR,CRP and TNF-αin the study group were lower than those in the reference group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of ethinylestradiol and cyproterone acetate and pioglitazone in the treatment of PCOS can improve insulin resistance,reduce the levels of serum inflammatory factors and reproductive hormones,with high safety.